The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Horizon scan of novel and upcoming AML therapies
Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA, summarizes the latest updates in the field of acute myeloid leukemia (AML), highlighting a new menin inhibitor and studies of novel combinations of IDH inhibitors and FLT3 inhibitors, such as with the BCL2 inhibitor venetoclax, as well as the future role of antibody-drug conjugates, bispecific antibodies and CAR T-cell therapy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
